A potent efficacy of pioglitazone on alcoholic and non-alcoholic fatty liver disease in type 2 diabetic mellitus
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000046797
- Lead Sponsor
- Tokyo Teishin Hospital
- Brief Summary
In patients with fatty liver, the HbA1c, AST, ALT, and gGTP levels significantly decreased after pioglitazone treatment than before (P<0.01). The AST and ALT levels, but not the gGTP level, and the FIB-4 index significantly decreased after pioglitazone addition in the AFLD group, similar to that in the NAFLD group (P<0.05 and P<0.01, respectively). Similar effects were observed following low-dose pioglitazone treatment (below 7.5 mg/day) (P<0.05) in T2D patients with AFLD and NAFLD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who refused to participate in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method